2022 Volume 29 Issue 2 Pages 144-148
The shortage of donors for transplantation is a universal problem. The use of marginal donors is one source to increase supply. However, recipients with marginal donor graft experience a higher incidence of primary nonfunction and delayed graft function (DGF). Recently, ex vivo machine perfusion (MP) is used to reduce the incidence of DGF by decreasing the ischemic damaged graft. In addition, MP provides for assessing graft viability that is essential for optimal organ allocation. The original MP for kidney and liver graft were developed in our institute. The, first multi-center clinical trial (UMIN000038181) for marginal kidney transplantation in Japan has been started since 2020. The study design is short time hypothermic oxygenated end-ischemic perfusion for brain death marginal and DCD kidney graft. As a results so far, no trouble related MP were seen. All case was HD free at the time of discharge. Current status of MP is reviewed this context.
